172 related articles for article (PubMed ID: 20573667)
1. Minimizing the toxicity of aminoglycosides in cystic fibrosis.
Smyth AR
J R Soc Med; 2010 Jul; 103 Suppl 1(Suppl 1):S3-5. PubMed ID: 20573667
[No Abstract] [Full Text] [Related]
2. Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs?
Vandenbussche HL; Klepser ME
Lancet; 2005 Feb 12-18; 365(9459):547-8. PubMed ID: 15708080
[No Abstract] [Full Text] [Related]
3. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy.
Hoffmann IM; Rubin BK; Iskandar SS; Schechter MS; Nagaraj SK; Bitzan MM
Pediatr Pulmonol; 2002 Nov; 34(5):375-7. PubMed ID: 12357482
[TBL] [Abstract][Full Text] [Related]
4. Tobramycin dosing in cystic fibrosis.
Smyth A; Touw D; Tan KH; Bertenshaw C; Stableforth D
Lancet; 2005 May 21-27; 365(9473):1767-8. PubMed ID: 15910946
[No Abstract] [Full Text] [Related]
5. Unwarranted use of intravenous aminoglycosides at UK paediatric cystic fibrosis centres.
Ditchfield N; Carroll WD; Gilchrist FJ
J Cyst Fibros; 2019 Nov; 18(6):e58-e59. PubMed ID: 31522925
[No Abstract] [Full Text] [Related]
6. Ototoxicity of aminoglucoside antibiotics in long-term treatment for cystic fibrosis.
Crifo S; Antonelli M; Gagliardi M; Lucarelli N; Marcolini P
Int J Pediatr Otorhinolaryngol; 1980 Sep; 2(3):251-3. PubMed ID: 6821312
[No Abstract] [Full Text] [Related]
7. Cystic fibrosis, aminoglycoside treatment and acute renal failure: the not so gentle micin.
Bockenhauer D; Hug MJ; Kleta R
Pediatr Nephrol; 2009 May; 24(5):925-8. PubMed ID: 19005685
[TBL] [Abstract][Full Text] [Related]
8. Technical report: precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs.
Prober CG; Walson PD; Jones J
Pediatrics; 2000 Dec; 106(6):E89. PubMed ID: 11099632
[TBL] [Abstract][Full Text] [Related]
9. Tobramycin treatment of pseudomonas aeruginosa infections in cystic fibrosis.
Hoff GE; Schiotz PO; Paulsen J
Scand J Infect Dis; 1974; 6(4):333-7. PubMed ID: 4217466
[No Abstract] [Full Text] [Related]
10. Lack of concordance in the use and monitoring of intravenous aminoglycosides in UK cystic fibrosis centers.
Tan KH; Hyman-Tylor P; Mulheran M; Knox A; Smyth A
Pediatr Pulmonol; 2002 Feb; 33(2):165. PubMed ID: 11802256
[No Abstract] [Full Text] [Related]
11. Tobramycin ototoxicity. Repeated courses of high dosage treatment in children with cystic fibrosis.
Thomsen J; Friis B; Jensen K; Bak-Pedersen K; Larsen PK
J Antimicrob Chemother; 1979 May; 5(3):257-60. PubMed ID: 479061
[No Abstract] [Full Text] [Related]
12. Errors associated with applying decision support by suggesting default doses for aminoglycosides.
Eslami S; Abu-Hanna A; de Keizer NF; de Jonge E
Drug Saf; 2006; 29(9):803-9. PubMed ID: 16944965
[TBL] [Abstract][Full Text] [Related]
13. Aminoglycoside-associated hypomagnesaemia in children with cystic fibrosis.
Akbar A; Rees JH; Nyamugunduru G; English MW; Spencer DA; Weller PH
Acta Paediatr; 1999 Jul; 88(7):783-5. PubMed ID: 10447142
[TBL] [Abstract][Full Text] [Related]
14. Aminoglycoside ototoxicity susceptibility in cystic fibrosis.
Mulrennan SA; Helm J; Thomas RB; Dodd M; Jones A; Webb K
Thorax; 2009 Mar; 64(3):271-2. PubMed ID: 19252031
[No Abstract] [Full Text] [Related]
15. Once-daily dosed gentamicin is more nephrotoxic than once-daily dosed tobramycin in clinically infected patients.
van Maarseveen E; van Buul-Gast MC; Abdoellakhan R; Gelinck L; Neef C; Touw D
J Antimicrob Chemother; 2014 Sep; 69(9):2581-3. PubMed ID: 24872345
[No Abstract] [Full Text] [Related]
16. Tobramycin inhalation solution (Bethkis) for cystic fibrosis.
Med Lett Drugs Ther; 2014 Jun; 56(1445):51-2. PubMed ID: 24956309
[No Abstract] [Full Text] [Related]
17. Acute renal failure in CF patients chronically infected by the Liverpool epidemic Pseudomonas aeruginosa strain (LES).
Al-Aloul M; Miller H; Stockton P; Ledson MJ; Walshaw MJ
J Cyst Fibros; 2005 Sep; 4(3):197-201. PubMed ID: 15967735
[TBL] [Abstract][Full Text] [Related]
18. Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity.
Prayle A; Smyth AR
Curr Opin Pulm Med; 2010 Nov; 16(6):604-10. PubMed ID: 20814306
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of aztreonam combined with tobramycin and gentamicin against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.
Bosso JA; Saxon BA; Matsen JM
Antimicrob Agents Chemother; 1987 Sep; 31(9):1403-5. PubMed ID: 3118798
[TBL] [Abstract][Full Text] [Related]
20. [TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients].
Pierart F
Rev Med Liege; 2013 Sep; 68(9):486-8. PubMed ID: 24180205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
